# Codex Phase 04 serialized integration — 2026-09-21 Vancouver

## DECISIONS FOR SKY

- **Review the exact integrated candidate:** Recommendation: use a fresh independent reviewer before any owner merge/push. Alternative: keep the local branch on hold. Impact: no release occurs in this window.
- **FDA-004 live proof:** Recommendation: retain DEFERRED until separately authorized live evidence exists. Alternative: leave the finding open. Impact: no runtime PASS claim.
- **04B follow-ups:** Recommendation: carry accepted handoff D-04B-1 through D-04B-3 to separate owner review. Alternative: defer. Impact: the noted deletion copy and Phase 05 questions remain pending.

## What changed

Branch `codex/flagstone-phase04-integration-20260921` preserves accepted 04A and 04B histories, then adds the reviewed 04B manifest Option B, its required guard assertion, and a stale policy comment correction. Tested code SHA `fa9f453589f3aa8a729cca7f8c50942714dee4af`, tree `b4654fea3256ed29effe555973aade1965ef6e3d`. This report and the detailed receipt/handoff are documentation-only additions. The primary checkout was not written.

## Gates

04A-only focused Jest: 15/15 suites and 387/387 tests. Combined focused Jest: 21/21 suites and 484/484 tests. Phase 03C disposable replay: 208/208. Phase 03B disposable rollback/reapply: PASS. `npx tsc --noEmit`: exit 0. `npx eslint src --ext .ts,.tsx`: exit 0, 0 errors, 90 accepted warnings. `npx jest --ci -w 3`: exit 0, 299/299 suites, 4,480 passed, 32 todo, 0 failed. Full command detail and outputs are in `phase04/20260922T032010Z-final-integration/FINAL_INTEGRATION.md`.

## What's left

One fresh independent acceptance review of the final receipt commit. FDA-004 live proof remains deferred. No production/staging contact, migration apply, deployment, push, or `main` change occurred.
